← Leaderboards
Elliot J Androphy
Indiana University Indianapolis
$24,340,128
Attributed
$27,538,678
Total exposure
22
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,538,678 · 22
By mechanism
R01$22,083,834 · 9
R21$3,397,377 · 7
R33$718,096 · 1
R43$574,293 · 2
T32$517,630 · 1
P30$222,448 · 1
Top collaborators
- Kevin Hodgetts5 shared
- Christian L. Lorson5 shared
- Samy Meroueh5 shared
- Zhijian Lu2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsProteinsApplications GrantsLeadSeriesBiologicalPropertyComplexProgramsMaintenanceGrantHuman PapillomavirusMediatingInsightMessenger RnaResearch StudyInvestigationGeneticIn VivoPathway InteractionsMutationGenetic TranscriptionDesignMolecular
Grant awards (90)
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection$657,376
R01 · FY2025 · CA · contact PI
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection$588,858
R01 · FY2024 · CA · contact PI
Development of a mouse model to test HPV Antiviral compounds$237,750
R21 · FY2024 · AI · contact PI
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection$607,244
R01 · FY2023 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$382,182
R01 · FY2023 · NS · contact PI
Development of a mouse model to test HPV Antiviral compounds$198,125
R21 · FY2023 · AI · contact PI
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection$645,142
R01 · FY2022 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$384,780
R01 · FY2022 · NS · contact PI
Small Molecule E6 Inhibitors to Treat Dysplasia Caused by HPV Infections$298,527
R43 · FY2022 · AI
Small Molecule E6 Inhibitors to Treat Oropharyngeal Cancers Caused by HPV Infections$275,766
R43 · FY2022 · DE
Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection$632,904
R01 · FY2021 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$384,780
R01 · FY2021 · NS · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$386,415
R01 · FY2020 · NS · contact PI
Control of Papillomavirus Expression and Transformation$406,635
R01 · FY2019 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$386,779
R01 · FY2019 · NS · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$212,328
R33 · FY2019 · NS · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$505,768
R33 · FY2018 · NS · contact PI
Control of Papillomavirus Expression and Transformation$370,500
R01 · FY2018 · CA · contact PI
Control of Papillomavirus Expression and Transformation$370,500
R01 · FY2017 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$341,250
R01 · FY2017 · NS · contact PI
The Indiana Cutaneous Biological Research Training Program$117,250
T32 · FY2017 · AR · contact PI
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA$431,954
R21 · FY2016 · NS · contact PI
Optimization of a novel series of thiazolopyridines for the treatment of SMA$420,850
R21 · FY2016 · NS
Control of Papillomavirus Expression and Transformation$370,500
R01 · FY2016 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$341,250
R01 · FY2016 · NS · contact PI
The Indiana Cutaneous Biological Research Training Program$147,408
T32 · FY2016 · AR · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$55,689
R01 · FY2016 · NS · contact PI
Optimization of a novel series of thiazolopyridines for the treatment of SMA$447,563
R21 · FY2015 · NS
Control of Papillomavirus Expression and Transformation$370,500
R01 · FY2015 · CA · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$340,848
R01 · FY2015 · NS · contact PI
Toward drug treatment of spinal muscular atrophy: Mechanism of action$195,000
R21 · FY2015 · NS · contact PI
The Indiana Cutaneous Biological Research Training Program$114,489
T32 · FY2015 · AR · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$337,451
R01 · FY2014 · NS · contact PI
Functions of Papillomavirus E6$290,937
R01 · FY2014 · CA · contact PI
Toward drug treatment of spinal muscular atrophy: Mechanism of action$260,650
R21 · FY2014 · NS · contact PI
The Indiana Cutaneous Biological Research Training Program$138,483
T32 · FY2014 · AR · contact PI
The COPA vesicle protein and pathogenesis of spinal muscular atrophy$340,871
R01 · FY2013 · NS · contact PI
Functions of Papillomavirus E6$281,939
R01 · FY2013 · CA · contact PI
Cooperative lead development program for treatment of spinal muscular atrophy$596,573
R01 · FY2012 · HD · contact PI
Functions of Papillomavirus E6$299,935
R01 · FY2012 · CA · contact PI
Cooperative lead development program for treatment of spinal muscular atrophy$640,547
R01 · FY2011 · HD · contact PI
Small Molecule Inhibitors of Oncogenic Human Papillomavirus$315,474
R01 · FY2011 · CA · contact PI
Control of Papillomavirus Expression and Transformation$312,214
R01 · FY2011 · CA · contact PI
Functions of Papillomavirus E6$282,715
R01 · FY2011 · CA · contact PI
Cooperative lead development program for treatment of spinal muscular atrophy$710,591
R01 · FY2010 · HD · contact PI
Control of Papillomavirus Expression and Transformation$341,289
R01 · FY2010 · CA · contact PI
Small Molecule Inhibitors of Oncogenic Human Papillomavirus$339,782
R01 · FY2010 · CA · contact PI
Functions of Papillomavirus E6$252,560
R01 · FY2010 · CA · contact PI
Testing Compounds that Increase SMN levels for Efficacy in Mouse Models of SMA$218,425
R21 · FY2010 · NS · contact PI
Functions of Papillomavirus E6$77,568
R01 · FY2010 · CA · contact PI
Control of Papillomavirus Expression and Transformation$360,126
R01 · FY2009 · CA · contact PI
Small Molecule Inhibitors of Oncogenic Human Papillomavirus$339,522
R01 · FY2009 · CA · contact PI
Testing Compounds that Increase SMN levels for Efficacy in Mouse Models of SMA$265,611
R21 · FY2009 · NS · contact PI
Optimization of drug-like compounds for treatment of spinal muscular atrophy$253,125
R21 · FY2009 · HD · contact PI
Control of Papillomavirus Expression and Transformation$9,510
R01 · FY2009 · CA · contact PI
Control of Papillomavirus Expression and Transformation$360,126
R01 · FY2008 · CA · contact PI
Small Molecule Inhibitors of Oncogenic Human Papillomavirus$354,628
R01 · FY2008 · CA · contact PI
Functions of Human Papillomavirus E6$310,653
R01 · FY2008 · CA · contact PI
Optimization of drug-like compounds for treatment of spinal muscular atrophy$225,000
R21 · FY2008 · HD · contact PI
High Throughput Screen for SMA$25,000
R03 · FY2008 · MH · contact PI
Control of Papillomavirus Expression and Transformation$360,126
R01 · FY2007 · CA · contact PI
Functions of Human Papillomavirus E6$310,653
R01 · FY2007 · CA · contact PI
High Throughput Screen for Compounds to Treat Papillomavirus Induced Cancers$119,919
R21 · FY2007 · CA · contact PI
Control of Papillomavirus Expression and Transformation$345,461
R01 · FY2006 · CA · contact PI
Functions of Human Papillomavirus E6$286,461
R01 · FY2006 · CA · contact PI
High Throughput Screen for Compounds to Treat Papillomavirus Induced Cancers$123,405
R21 · FY2006 · CA · contact PI
Control of Papillomavirus Expression and Transformation$353,775
R01 · FY2005 · CA
Functions of Human Papillomavirus E6$293,355
R01 · FY2005 · CA
Papillomavirus Inhibitors for AIDS-related Malignancies$279,388
R01 · FY2005 · CA
Control of Papillomavirus Expression and Transformation$393,776
R01 · FY2004 · CA
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$318,000
R01 · FY2004 · NS
Functions of Human Papillomavirus E6$293,355
R01 · FY2004 · CA
Papillomavirus Inhibitors for AIDS-related Malignancies$279,388
R01 · FY2004 · CA
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$32,400
R01 · FY2004 · NS
Control of Papillomavirus Expression and Transformation$353,775
R01 · FY2003 · CA
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$318,000
R01 · FY2003 · NS
Papillomavirus Inhibitors for AIDS-related Malignancies$279,388
R01 · FY2003 · CA
Control of Papillomavirus Expression and Transformation$351,551
R01 · FY2002 · CA
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$318,000
R01 · FY2002 · NS
Papillomavirus Inhibitors for AIDS-related Malignancies$279,388
R01 · FY2002 · CA
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$249,620
R01 · FY2001 · NS
FUNCTIONS OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEIN$142,925
R01 · FY2001 · CA
FUNCTIONS OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEIN$138,655
R01 · FY2001 · CA
CORE--AIDS RELATED MALIGNANCY$129,540
P30 · FY2001 · AI
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$59,420
R01 · FY2001 · NS
CORE--AIDS RELATED MALIGNANCY$0
P30 · FY2001 · AI
MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHY$309,040
R01 · FY2000 · NS
CONTROL OF PAPILLOMAVIRUS EXPRESSION AND TRANSFORMATIO$283,213
R01 · FY2000 · CA
FUNCTIONS OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEIN$275,578
R01 · FY2000 · CA
CORE--AIDS RELATED MALIGNANCY$92,908
P30 · FY2000 · AI